Datafolha Survey Highlights Breast Cancer Information Gaps as Vitória Expands Screening
The reduction in breast cancer mortality in Brazil has been 4.5% since 1990, while in Europe this decrease was 23.1% during the same period, according to an analysis by the Global Burden of Disease. While Brazilian legislation guarantees routine mammograms for women over 40 within strict timeframes—such as 30 days for complementary exams following an altered result and 60 days for treatment initiation—the reality on the ground differs sharply. Guilherme Novita, president of the Brazilian Society of Mastology (SBM), noted that equipment is heavily concentrated in the South and Southeast regions, pushing the average wait time for treatment to 150 days in the public system.
Information Deficits Persist Among Patients
A nationwide survey conducted by the Datafolha Institute with sponsorship from AstraZeneca reveals significant gaps in patient communication during the breast cancer journey. The survey indicates that 36% of women reported feeling a lack of clarity in how medical exams and treatments are communicated, while 33% stated they need more information about these procedures. Furthermore, 45% of women surveyed admitted to having numerous doubts regarding breast cancer, with 39% having no idea what the term “recidiva” (recurrence) means.
Luciana Holtz, president of the Oncoguia Institute, emphasized that accessible information must accompany medical treatment. “The useful and quality information needs to accompany the patient at all stages of the journey,” Holtz stated. The survey found that 62% of respondents believe clear content helps them understand disease progression and recovery prospects.
Scientific Complexity and Modern Diagnostic Options
Modern oncology requires personalized care due to varying tumor types, subtypes, and biomarkers. Danilo Lopes, director of the medical areas of oncology and rare diseases at AstraZeneca, explained that modern medicine evaluates specific tumor characteristics within distinct biological subtypes. “Today we know that breast cancer is not a unique disease,” Lopes stated, highlighting advanced tools such as liquid biopsies that allow physicians to monitor disease changes over time less invasively.
Vitória Increases Access to Mammograms for October
In response to local diagnostic challenges, the municipality of Vitória in Espírito Santo is taking direct action. The National Cancer Institute (Inca) estimates that Espírito Santo will record 950 new breast cancer cases, with 110 expected in Vitória. To counter these figures during the Outubro Rosa campaign, the Vitória Municipal Health Secretariat has made 5,000 mammograms and 3,500 breast and transvaginal ultrasounds available—nearly four times the monthly average of 1,300 procedures.
Magda Lamborghini, municipal health secretary of Vitória, explained that women can visit any of the 29 municipal health units for an evaluation to receive a requisition for screening regardless of age if indicated. Additionally, the capital has established a dedicated tracking program to guide patients from initial suspicion through treatment initiation to prevent them from getting lost between appointments and referrals.
Frequently Asked Questions
What are the legal timeframes for breast cancer diagnosis and treatment in Brazil?
Brazilian federal law guarantees that women over 40 have the right to routine mammograms. Furthermore, legislation mandates that if a mammogram shows an altered result, the patient must receive complementary exams within a maximum of 30 days, and treatment must begin within 60 days of a confirmed cancer diagnosis.
How many mammograms does the municipality of Vitória offer during Pink October?
Vitória is providing 5,000 mammograms during the October campaign—nearly four times its standard monthly average of 1,300 procedures—along with 3,500 breast and transvaginal ultrasounds.
What percentage of women reported communication gaps in the Datafolha survey?
The survey indicates that 36% of women reported feeling a lack of clarity in communication regarding their exams and treatments, while 33% stated a need for more information.
What is a liquid biopsy in the context of breast cancer treatment?
As explained by AstraZeneca director Danilo Lopes, a liquid biopsy is an increasingly sophisticated and less invasive test used to evaluate tumor biomarkers and track alterations in the disease over time to assist medical decision-making.
Related reading